Skip to content

Study · In vitro (cells) · 2007

3 results

The IGF-I splice variant MGF increases progenitor cells in ALS, dystrophic, and normal muscle.

Ates K, Yang SY, Orrell RW, Sinanan AC, Simons P, Solomon A, Beech S, Goldspink G, Lewis MP

FEBS letters21 May 2007Cited by 70 (Europe PMC)

PMID17531227 (opens in a new tab)DOI10.1016/j.febslet.2007.05.030 (opens in a new tab)PepBankPUB-17531227
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In primary human muscle cell cultures from healthy subjects, the MGF E domain peptide significantly increased the number of progenitor cells.

    In plain wordsIn cells from healthy donors, the MGF peptide increased the number of muscle progenitor cells.

    Peptide
    MGF / PEG-MGF
    Outcome
    IncreaseProgenitor cell number in healthy muscle cultures
    Study

    humann: not reported in source

    Human primary muscle cell cultures
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the E domain peptide of IGF-IEc (MGF) significantly increased the numbers of progenitor cells in healthy and diseased muscle.
    1 context sentence
    Summary · context
    The effects of muscle splice variants of insulin-like growth factor I (IGF-I) on proliferation and differentiation were studied in human primary muscle cell cultures from healthy subjects as well as from muscular dystrophy and ALS patients.
  2. 02LabIn vitro (cells)Activity measurement

    In primary muscle cell cultures from muscular dystrophy and ALS patients, the MGF E domain peptide significantly increased the number of progenitor cells.

    In plain wordsIn cells from donors with muscular dystrophy or ALS, the MGF peptide increased the number of muscle progenitor cells.

    Peptide
    MGF / PEG-MGF
    Outcome
    IncreaseProgenitor cell number in diseased muscle cultures
    Study

    humann: not reported in source

    Human primary muscle cell cultures
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the E domain peptide of IGF-IEc (MGF) significantly increased the numbers of progenitor cells in healthy and diseased muscle.
    1 context sentence
    Summary · context
    The effects of muscle splice variants of insulin-like growth factor I (IGF-I) on proliferation and differentiation were studied in human primary muscle cell cultures from healthy subjects as well as from muscular dystrophy and ALS patients.
  3. 03LabIn vitro (cells)Mechanism

    In primary human muscle cell cultures, the MGF E peptide blocked the myogenic differentiation pathway, which increased the progenitor cell pool.

    In plain wordsIn cells, the MGF peptide blocked muscle cell maturation and so kept more progenitor cells.

    Peptide
    MGF / PEG-MGF
    Outcome
    DecreaseMyogenic differentiation
    Study

    humann: not reported in source

    Human primary muscle cell cultures
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MGF E peptide blocks this pathway, resulting in an increased progenitor (stem) cell pool and thus potentially facilitating repair and maintenance of this postmitotic tissue.
    1 context sentence
    Summary · context
    The effects of muscle splice variants of insulin-like growth factor I (IGF-I) on proliferation and differentiation were studied in human primary muscle cell cultures from healthy subjects as well as from muscular dystrophy and ALS patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.